Patent SG-11201811292R-A (SG)
Title: Compositions and methods for the depletion of cells
Inventor: NIXON ANDREW
IPC: C07K16/28
Filed: 2017-06-19
Abstract: Luminescence (7) 800000 600000 400000 200000 0 43- Isotype Abi CD45 Abi -str• Isotype Ab2 CD45 Ab2 Isotype Ab3 CD45 Ab3 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 December 2017 (21.12.2017) WIP01 PCT IiiimmomiolollmolommoololommoillonnovoimIE (10) International Publication Number WO 2017/219025 Al (51) International Patent Classification: A61K 39/395 (2006.01) Cl 2N 5/00 (2006.01) CO7K 16/28 (2006.01) (21) International Application Number: PCT/US2017/038151 (22) International Filing Date: 19 June 2017 (19.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/351,725 17 June 2016 (17.06.2016) US 62/351,778 17 June 2016 (17.06.2016) US 62/437,729 22 December 2016 (22.12.2016) US 62/437,756 22 December 2016 (22.12.2016) US 62/448,768 20 January 2017 (20.01.2017) US 62/448,782 20 January 2017 (20.01.2017) US (71) Applicant: MAGENTA THERAPEUTICS, INC. [US/US]; 50 Hampshire Street, 8th Floor, Cambridge, MA 02139 (US). (72) Inventors: NIXON, Andrew; 41 Evergreen Lane, Hanover, MA 02339 (US). MORROW, Dwight; 1230 Wa- terford Road, West Chester, PA 19380 (US). HARTIGAN, Adam; 84 Harvard Avenue, Apt. 2, Brookline, MA 02446 (US). (74) Agent: COWLES, Cristin H. et al.; Womble Bond Dick- inson (US) LLP, P.O. Box 7037, Atlanta, GA 30357-0037 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (54) Title: COMPOSITIONS AND METHODS FOR THE DEPLETION OF CELLS FIG. 1 Reh Cell Viability CD45-Saporin -12 -10 -8 Concentration LOG(M) (57) : The invention provides compositions and methods useful for the depletion of cells, such as CD45+, CD135+, CD34+, CD90+, and/or CD110+ cells, and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune O diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the O engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant [Continued on next page] WO 2017/219025 Al MIDEDIMOMOIDEIRMEM001101ROMMOMEEM DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) procedure.